echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The market of anti ed drugs has broken through 10 billion scale, and Jinge and Viagra are equally divided

    The market of anti ed drugs has broken through 10 billion scale, and Jinge and Viagra are equally divided

    • Last Update: 2017-12-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, sildenafil citrate tablets developed by Changshan Pharmaceutical Co., Ltd were officially approved by CFDA for production registration Since Pfizer's Viagra entered the country in 1998, there have been three domestic sildenafil preparations, namely, Jinge of Baiyunshan Pharmaceutical in Guangzhou, wanfile of Epson / pharmaceutical in Jiangsu and wanyeqiang of Changshan biochemical pharmaceutical in Hebei Its main purpose is to treat ed (erectile dysfunction) and make contributions to the human liberation movement Driven by the aging of the global population, and under the pressure of modern work and life, the number of ED patients is increasing year by year According to the data of the World Health Organization, the global male erectile dysfunction accounts for about 10%, only the United States has 18 million erectile dysfunction, the peak annual sales of Pfizer's Viagra exceeds 2 billion US dollars; from 2001 to 2016, Pfizer has achieved 28.5 billion US dollars With the progress of human beings and the development of science, China has put the four diseases unique to men on the agenda Sexual dysfunction is the second largest disease after prostate disease, in addition to male infertility and sexually transmitted diseases According to the latest statistical data in 2016, the prevalence rate of ED in the population over 40 years old is 46.2%; 56% of the patients aged 30-50 years old account for the proportion; therefore, the field of ED treatment has become a market of great attention According to the blue book of China's six terminal drug markets, from 2012 to 2016, China's anti ED market has exceeded 10 billion yuan in five years, reaching 11.028 billion yuan, with an average annual growth rate of 28.80% There are more than 100 million men with erectile dysfunction in different degrees in the retail market of prescription drugs, which is basically similar to the incidence of diabetes The most difficult problem is that the treatment rate is less than 8% In the process of personal ED treatment, patients often take their own course or adopt self-treatment Many patients fail to receive standardized drugs in time and reasonably, and the huge market needs to be expanded Another feature is that self medication accounts for more than 80% Therefore, under the situation that the sales volume of hospital market is only tens of millions of yuan, the retail market of drugstores has increased more than 40 times The data shows that in 2016, the sales scale of China's anti ed drugs market has reached 3.595 billion yuan, an increase of 26.41% over the previous year; among them, the domestic public hospital system is only about billion yuan, because this kind of drugs have not been listed in the medical insurance catalog, and the hospital market is only the tip of the iceberg The vast market comes from the retail terminal of drugstores The main varieties are sildenafil, tadalafil and vardenafil The dosage of apomorphine hydrochloride sublingual tablets, prostaglandin E1 cream, testosterone patch and dapoxetine were less Driven by domestic sildenafil and jingotima, it is estimated that the sales volume of domestic anti ed chemicals will reach 4.5 billion in 2017 As we all know, the retail drugstore is an important part of the medical front, especially in OTC and OTC double cross drug terminals It provides a good hotbed for ED resistant sildenafil After Pfizer's Viagra has entered the Chinese market, it has felt the pulse and carried out a lot of activities But one is that the price of Viagra is too high, and the other is that people's spending on it is still in a period of hesitation After the listing of Jinge in 2014, Baiyunshan Pharmaceutical broke the monopoly of foreign enterprises on China's ED market On the other hand, people 's expenditure on health care and medical care has changed dramatically In 2016, the sales volume of sildenafil citrate tablets in retail pharmacies reached a market scale of 2.42 billion yuan, an increase of 50.78% over the previous year, and an increase of nearly 7% over the previous year Among them, Pfizer's Viagra accounts for 60% and Guangzhou Baiyunshan's Jinge quickly accounts for 40% of the market share At present, according to the data of the first three quarters of 2017, it is predicted that the sales volume of sildenafil citrate tablets in retail pharmacies will reach a market scale of 2.886 billion yuan in 2017, with a growth rate of nearly 20% over the previous year After Baiyunshan Jinge has become the second main variety of Baiyunshan, Guangyao, this year Jinge continues to make rapid progress, with a total sales target of 1.8 billion yuan In 2016, with the outstanding contribution of Jinge, the domestic anti ED market reached 3.595 billion yuan, an increase of 26.66% over the previous year's 2.84 billion yuan In the anti ED market, tadalafil is one of the top 10 retail drugs for urinary tract and kidney invigoration in domestic pharmacies, ranking eighth Tadalafil is a drug jointly developed by Eli Lilly and IKOs, with the trade name of Cialis Hierlich is characterized by a long half-life, which can achieve 36 hours of efficacy, with strong safety and cost performance; meanwhile, it has been used to treat male ed combined with benign prostatic hyperplasia, thus stimulating the market growth; in 2016, the global sales amount of hierlich reached 2.472 billion US dollars, with a growth rate of 6.97% compared with the previous year; in the first half of 2017, it still achieved a performance of 1.161 billion US dollars The company is listed in China and has won high praise According to the data, in 2015, ciely accounted for 14.7% of the market of therapeutic ed drugs In 2016, the sales volume of xiaili tablets in retail drugstores will reach 318 million yuan, and it is predicted that the sales volume of xiaili tablets in retail drugstores will reach 365 million yuan in 2017, with a year-on-year growth rate of 14.78% Among them, Chinese patent medicine plays an important role in the market of Tonifying the kidney and strengthening yang, among which Shenbao tablet, Liuwei Dihuang pill, capsule, ancient Han health essence, Zhibai Dihuang pill are also the top 10 varieties of retail drugs for urinary tonifying the kidney in domestic pharmacies Among the top 10 manufacturers of Urology and kidney tonifying retail in domestic pharmacies, the top five are Jiangxi Huiren pharmaceutical, Pfizer pharmaceutical, Guangyao Baiyunshan, Tongrentang and Henan Wanxi pharmaceutical.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.